Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (240)	10/4/2002 1:15:24 PM
From: RCMac	Read Replies (1) \| Respond to of 897

Utah mining company subsidiary cures malaria, fungal skin infections, vaginal infections, urinary tract infections, tonsilitis, pharingitis, gonorrhea, conjunctivitis, upper respiratory tract infections, nasal and sinus problems and MRSA infections. All this with its versatile "ASAP Solution(R)", tested on 60 patients in Ghana, which solution "has just received [the company's] first international drug approval." Readallaboutit: Message 18073164 Also the company has been "chosen by the [entirely fictional] United States Senate Committee for Homeland Defense" for its "ASAP Solution(TM) as a product that is 'proven to kill bacteria such as Staph, TB, E-coli, Salmonella, a number of yeasts and even the Anthrax spore.'" newswire.ca CFTN currently trades for 33 cents on the pink sheets, up 2 cents on the day. --RCM